- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07718893
CITE: Clinical Inference Tethered to Evidence - a Retrieve-and-verify Layer for AI Care Plans (CITE)
16. juli 2026 oppdatert av: Sanjay Basu, Waymark
A Randomized Controlled Trial of CITE (Clinical Inference Tethered to Evidence), an Evidence-Grounding Retrieve-and-Verify Layer That Flags Unsupported and Inappropriate Recommendations in AI-Generated Care Plans, Versus AI With Safety Guardrails Alone and Unassisted Care, in Medicaid Primary Care
This trial evaluates CITE, a retrieve-and-verify layer that audits an AI-generated care plan against a full-text evidence corpus and flags patient-specific codifiable safety hazards to the clinician.
The co-primary outcomes are how accurately CITE flags these hazards (sensitivity and specificity versus blinded clinician adjudication) and its clinician alert burden and acceptance, compared with AI care plans using safety guardrails alone and with unassisted clinician care, in Medicaid primary care.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
Patients are randomized 1:1:1 to (1) unassisted clinician care; (2) AI-generated care plan with safety guardrails; (3) AI-generated care plan with safety guardrails plus CITE.
CITE audits the finalized plan against a frozen, versioned evidence corpus and returns physician-facing flags for patient-specific codifiable safety hazards (a recommended drug contraindicated by this patient's diagnosis or laboratory value; a drug-allergy conflict; a dropped high-risk medication; a guideline-indicated therapy omitted for an active diagnosis; a stated quantity refuted by the corpus), each with a verbatim quote and citation; the clinician retains decision authority.
Randomization uses a deterministic HMAC permuted-block scheme; outcome assessors are blinded to arm.
The co-primary outcomes are (1) the diagnostic accuracy (sensitivity and specificity) of CITE against blinded clinician adjudication, and (2) clinician alert burden (flags per encounter) and acceptance, comparing the CITE arm with the guardrail arm; both are estimable at the enrolled sample size because they do not depend on a rare between-arm event.
The unresolved codifiable-hazard rate by arm is reported as a descriptive secondary: codifiable hazards are infrequent, so the trial is not powered for a between-arm efficacy contrast on hazard reduction.
A prior trial of a different mechanism (a generic deterministic rule-corpus that surfaced roughly 30 or more flags per encounter and was uninformative) was completed with null results and is registered separately; this trial evaluates a materially different, patient-specific intervention and set of outcomes.
Determined exempt by WCG IRB (low risk).
Analysis is pre-registered on OSF (https://doi.org/10.17605/OSF.IO/ENXCW).
Studietype
Intervensjonell
Registrering (Antatt)
240
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
INCLUSION CRITERIA:
- Age 18 years or older.
- Medicaid-enrolled and attributed to a participating Waymark primary care site.
- Primary care encounter that requires clinical reasoning (not administrative-only).
- English-language clinical documentation.
EXCLUSION CRITERIA:
- Age less than 18 years.
- Hospice or palliative-care-exclusive care plan.
- Administrative-only or pharmacy-only encounter that does not surface a clinical decision to the supervising clinician.
- Encounter where the supervising clinician is the principal investigator.
- Enrollment in a competing AI-safety study within the prior 90 days.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Arm 1: Unassisted care
Clinician develops the care plan without AI assistance.
|
|
|
Aktiv komparator: Arm 2: AI with safety guardrails
AI-generated care plan produced with a safety-guardrail system prompt; no CITE.
|
AI-generated care plan produced under a safety-guardrail system prompt.
|
|
Eksperimentell: Arm 3: AI with safety guardrails plus CITE
AI-generated care plan with safety guardrails, then passed through CITE, which flags unsupported/inappropriate recommendations with evidence citations for the clinician.
|
AI-generated care plan produced under a safety-guardrail system prompt.
Reads the AI care-plan text and verifies each recommendation/claim against a full-text evidence corpus; returns physician-facing flags (commission/confabulation/unsupported/omission) with verbatim quotes and citations.
Clinician retains decision authority.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic accuracy of CITE against clinician adjudication
Tidsramme: Day 1 (index primary care encounter)
|
Sensitivity and specificity (with positive and negative predictive values) of the CITE checker for clinically consequential codifiable safety hazards, using blinded clinician adjudication of the plan as the reference standard.
Every plan contributes, so the estimate does not depend on a rare between-arm event.
Exact-binomial 95% confidence intervals; reported overall and by hazard family.
|
Day 1 (index primary care encounter)
|
|
Clinician alert burden (flags surfaced per encounter)
Tidsramme: Day 1 (index primary care encounter)
|
Number of safety flags surfaced to the clinician per encounter in the CITE arm versus the guardrail arm, with clinician acceptance rate.
Co-primary usability outcome: a verifier that surfaces an unmanageable number of flags is not deployable regardless of sensitivity (the prior-trial mechanism surfaced a median of about 30 per encounter).
Pre-registered acceptability ceiling: median CITE flags per encounter at or below three.
|
Day 1 (index primary care encounter)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinician action on CITE flags
Tidsramme: Day 1 (index primary care encounter)
|
Proportion of CITE flags accepted vs overridden by the clinician, by flag type (commission, confabulation, unsupported, omission).
|
Day 1 (index primary care encounter)
|
|
Unresolved codifiable safety-hazard rate by arm (descriptive)
Tidsramme: Day 1 (index primary care encounter)
|
Proportion of patient-specific codifiable-hazard checkpoints with an unresolved hazard in the finalized plan, by arm, with the Arm 3 minus Arm 2 difference and 95% confidence interval.
Pre-specified as descriptive and hypothesis-generating: codifiable hazards are infrequent, so the trial is not powered for a between-arm efficacy contrast on this measure at the enrolled sample size.
|
Day 1 (index primary care encounter)
|
|
Correction of codifiable hazards within 30 days
Tidsramme: Up to 30 days after the index encounter
|
Among checkpoints with a hazard in the finalized plan, the proportion acted on and corrected within 30 days (documented resolution, completed referral, or corrected order).
Proximal clinical effectiveness measure.
|
Up to 30 days after the index encounter
|
|
Completed referrals within 30 days
Tidsramme: Up to 30 days after the index encounter
|
Proportion of initiated referrals completed within 30 days.
|
Up to 30 days after the index encounter
|
|
Clinical safety composite (exploratory)
Tidsramme: Day 1 (index primary care encounter)
|
Four-component clinical safety composite carried from the prior trial.
Pre-specified as exploratory; underpowered at the planned sample size.
|
Day 1 (index primary care encounter)
|
|
30-day acute care utilization (exploratory)
Tidsramme: Up to 30 days after the index encounter
|
Emergency department visits and hospitalizations within 30 days.
Exploratory.
|
Up to 30 days after the index encounter
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. september 2026
Primær fullføring (Antatt)
1. juni 2027
Studiet fullført (Antatt)
1. september 2027
Datoer for studieregistrering
Først innsendt
13. juli 2026
Først innsendt som oppfylte QC-kriteriene
16. juli 2026
Først lagt ut (Faktiske)
22. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
22. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CITE-2026-02
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Pasientsikkerhet
-
Assiut UniversityRekrutteringSafety of Excision den nye tumorstørrelsenEgypt